At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
Pyridostigmine tabletsdrug
Likely dose
Pyridostigmine tablets 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of an ACh-E Inhibitor Upon Immune Activation Markers in HIV-1 Infected Patients Receiving Highly Active Antiretroviral Therapy (HAART) Showing an Incomplete Immune Response.
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·interventional·Posted Aug 20, 2007·Updated Nov 14, 2019
In Brief
A Phase 2 clinical trial evaluating Pyridostigmine tablets for HIV Infections. Completed, enrolled 7 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine whether the addition of Pyridostigmine to Highly Active Antiretroviral Therapy (HAART) increases the number of CD4+ T-cells in discordant patients in which viral load diminishes, but T-cell levels remain low after the initiation of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesMexico
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2007
Enrollment StartSep 2007
Primary CompletionNov 2008
Study CompletionJan 2009
TodayJul 2026
First PostedAug 20, 2007
Enrollment StartSep 1, 2007
Primary CompletionNov 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.9 years ago
Interventions
Pyridostigmine tabletsdrug
Patients will take 30mg tid PO for 12 weeks